Biology subjects

Bujotzek, A.

Publications and source records attributed to Bujotzek, A..

9 recordsLinked to original sources

bioRxiv2026

Can Folding Models Tell Binders from Bluffers? Evidence from POISK: The Patent-Derived Antibody Dataset

Structure prediction models are increasingly deployed as zero-shot digital screens in antibody design, operating under the assumption that high folding confidence implies true binding. However, rigorous validation of this premise has been limited by small test sets, narrow target diversity, and the risk of data leakage from training-adjacent structures. Here we introduce POISK: Patent-extracted Organization of Immunoglobulin Sequence Knowledge, a large-scale dataset derived from the US patent literature, comprising 89074 antibody-antigen records extracted from 10110 patents using an LLM-based pipeline. From this resource, we curate a balanced benchmark set of 22494 complexes: 11247 patent-validated binders without a known resolved structure paired with putative non-binders constructed from sequence-similar human repertoire antibodies. Using this dataset, we benchmark six leading structure prediction models (AlphaFold-Multimer, Boltz-2, IntelliFold v2, OpenFold3, Protenix-v1, and Protenix-v2) on their ability to discriminate binders from decoys. The best-performing model, Protenix-v2, achieves 72% pairwise accuracy over all pairs and 87% on the most confident half of predictions, and correctly identifies the true binder from a pool of 50 candidates in 29% of trials; this represents a substantial enrichment over random selection, yet remains far from reliable single-candidate identification. Structural consensus across models also discriminates binders from decoys, with pairwise accuracy reaching 73.1% when three or more models converge on a pose (DockQ>0.23, covering around 54.2% of pairs). Epitope localization remains unreliable: the best model contacts annotated epitope residues in only 62.8% of cases, indicating that binding discrimination does not establish accurate epitope localization. Our results suggest that current folding models provide useful but limited signal for antibody screening and should be complemented by orthogonal methods. We release POISK as a community resource for future benchmarking and model training.

bioinformatics↗

bioRxiv2025

Predicting the conformational flexibility of antibody and T-cell receptor CDRs

AbstractMany proteins are highly flexible and their ability to adapt their shape can be fundamental to their functional properties. We can now computationally predict a single, static protein structure with high accuracy. However, we are not yet able to reliably predict structural flexibility. A major factor limiting such predictions is the scarcity of suitable training data. Here, we focus on predicting the structural flexibility of the functionally important antibody and T-cell receptor CDR3 loops. We extracted a dataset of CDR3 like loop motifs from the PDB to create ALL-conformations, a dataset containing 1.2 million structures and more than 100,000 unique sequences. Using this dataset, we develop ITsFlexible a method classifying CDR3 flexibility, which outperforms all alternative approaches on our crystal structure datasets and successfully generalises to MD simulations. We also used ITsFlexible to predict the flexibility of three completely novel CDRH3 loops and experimentally determined their conformations using cryo-EM.

bioinformatics↗

bioRxiv2023

The Patent and Literature Antibody Database (PLAbDab): an evolving reference set of functionally diverse, literature-annotated antibody sequences and structures

Antibodies are key proteins of the adaptive immune system, and there exists a large body of academic literature and patents dedicated to their study and concomitant conversion into therapeutics, diagnostics, or reagents. These documents often contain extensive functional characterisations of the sets of antibodies the describe. However, leveraging these heterogeneous reports, for example to offer insights into the properties of query antibodies of interest, is currently challenging as there is no central repository through which this wide corpus can be mined by sequence or structure. Here, we present PLAbDab (the Patent and Literature Antibody Database), a self-updating repository containing over 150,000 paired antibody sequences and 3D structural models, of which over 65,000 are unique. Each entry in the database also contains the title and authors of its literature source. Here we describe the methods used to extract, filter, pair, and model the antibodies in PLAbDab, and showcase how PLAbDab can be searched by sequence, structure, or keyword. PLAbDab uses include annotating query antibodies with potential antigen information from similar entries, analysing structural models of existing antibodies to identify modifications that could improve their properties, and compiling bespoke datasets of antibody sequences/structures known to bind to a specific antigen. PLAbDab is freely available via Github (https://github.com/oxpig/PLAbDab) and as a searchable webserver (https://opig.stats.ox.ac.uk/webapps/plabdab/).

bioinformatics↗

bioRxiv2022

ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins.

Immune receptor proteins play a key role in the immune system and have shown great promise as biotherapeutics. The structure of these proteins is critical for understanding their antigen binding properties. Here, we present ImmuneBuilder, a set of deep learning models trained to accurately predict the structure of antibodies (ABodyBuilder2), nanobodies (NanoBodyBuilder2) and T-Cell receptors (TCRBuilder2). We show that ImmuneBuilder generates structures with state of the art accuracy while being far faster than AlphaFold2. For example, on a benchmark of 34 recently solved antibodies, ABodyBuilder2 predicts CDR-H3 loops with an RMSD of 2.81[A], a 0.09[A] improvement over AlphaFold-Multimer, while being over a hundred times faster. Similar results are also achieved for nanobodies, (NanoBodyBuilder2 predicts CDR-H3 loops with an average RMSD of 2.89[A], a 0.55[A] improvement over AlphaFold2) and TCRs. By predicting an ensemble of structures, ImmuneBuilder also gives an error estimate for every residue in its final prediction. ImmuneBuilder is made freely available, both to download (https://github.com/oxpig/ImmuneBuilder) and to use via our webserver (http://opig.stats.ox.ac.uk/webapps/newsabdab/sabpred). We also make available structural models for ~150 thousand non-redundant paired antibody sequences (https://zenodo.org/record/7258553).

bioinformatics↗

bioRxiv2021

ABlooper: Fast accurate antibody CDR loop structure prediction with accuracy estimation

Antibodies are a key component of the immune system and have been extensively used as biotherapeutics. Accurate knowledge of their structure is central to understanding their antigen binding function. The key area for antigen binding and the main area of structural variation in antibodies is concentrated in the six complementarity determining regions (CDRs), with the most important for binding and most variable being the CDR-H3 loop. The sequence and structural variability of CDR-H3 make it particularly challenging to model. Recently deep learning methods have offered a step change in our ability to predict protein structures. In this work we present ABlooper, an end-to-end equivariant deep-learning based CDR loop structure prediction tool. ABlooper rapidly predicts the structure of CDR loops with high accuracy and provides a confidence estimate for each of its predictions. On the models of the Rosetta Antibody Benchmark, ABlooper makes predictions with an average CDR-H3 RMSD of 2.49[A], which drops to 2.05[A] when considering only its 76% most confident predictions.

bioinformatics↗

bioRxiv2021

OCD.py - Characterizing immunoglobulin inter-domain orientations

SummaryInter-domain orientations between immunoglobulin domains are important for the modeling and engineering of novel antibody therapeutics. Previous tools to describe these orientations are applicable only to the variable domains of antibodies and T-cell receptors. We present the "Orientation of Cylindrical Domains (OCD)" tool, which employs a transferable approach to calculate inter-domain orientations for all immunoglobulin domains. Based on a reference structure, the OCD tool automatically builds a suitable reference coordinate system for each domain. Through alignment, the reference coordinate systems are transferred onto the sample to calculate six measures which fully characterize the inter-domain orientation. Availability and implementationThe OCD approach is implemented as a stand-alone Python script, OCD.py, which can handle multiple types of data input for the analysis of single structures and molecular dynamics trajectories alike. OCD.py is available at https://github.com/liedllab/OCD under MIT license. Supplementary InformationSupplementary information and data are available at Bioinformatics online.

bioinformatics↗

bioRxiv2020

Ab-Ligity: Identifying sequence-dissimilar antibodies that bind to the same epitope

Solving the structure of an antibody-antigen complex gives atomic level information of the interactions between an antibody and its antigen, but such structures are expensive and hard to obtain. Alternative experimental sources include epitope mapping and binning experiments which can be used as a surrogate to identify key interacting residues. However, their resolution is usually not sufficient to identify if two antibodies have identical interactions. Computational approaches to this problem have so far been based on the premise that antibodies with similar sequences behave similarly. Such approaches will fail to identify sequence-distant antibodies that target the same epitope. We present Ab-Ligity, a structure-based similarity measure tailored to antibody-antigen interfaces. Using predicted paratopes on model antibody structures, we assessed its ability to identify those antibodies that target highly similar epitopes. Most antibodies adopting similar binding modes can be identified from sequence similarity alone, using methods such as clonotyping. In the challenging subset of antibodies whose sequences differ significantly, Ab-Ligity is still able to predict antibodies that would bind to highly similar epitopes (precision of 0.95 and recall of 0.69). We compared Ab-Ligitys performance to an existing tool for comparing general protein interfaces, InterComp, and showed improved performance on antibody cases alongside a significant speed-up. These results suggest that Ab-Ligity will allow the identification of diverse (sequence-dissimilar) antibodies that bind to the same epitopes from large datasets such as immune repertoires. The tool is available at http://opig.stats.ox.ac.uk/resources.

bioinformatics↗

bioRxiv2019

Thera-SAbDab: the Therapeutic Structural Antibody Database

The Therapeutic Structural Antibody Database (Thera-SAbDab; http://opig.stats.ox.ac.uk/webapps/therasabdab) tracks all antibody- and nanobody-related therapeutics recognised by the World Health Organisation (WHO), and identifies any corresponding structures in the Structural Antibody Database (SAbDab) with near-exact or exact variable domain sequence matches. Thera-SAbDab is synchronised with SAbDab to update weekly, reflecting new Protein Data Bank entries and the availability of new sequence data published by the WHO. Each therapeutic summary page lists structural coverage (with links to the appropriate SAbDab entries), alignments showing where any near-matches deviate in sequence, and accompanying metadata, such as intended target and investigated conditions. Thera-SAbDab can be queried by therapeutic name, by a combination of metadata, or by variable domain sequence - returning all therapeutics that are within a specified sequence identity over a specified region of the query. The sequences of all therapeutics listed in Thera-SAbDab (461 unique molecules, as of 5th August 2019) are downloadable as a single file with accompanying metadata.

immunology↗

bioRxiv2018

The Therapeutic Antibody Profiler (TAP): Five Computational Developability Guidelines

Therapeutic monoclonal antibodies (mAbs) must not only bind to their target but must also be free from 'developability issues', such as poor stability or high levels of aggregation. While small molecule drug discovery benefits from Lipinski's rule of five to guide the selection of molecules with appropriate biophysical properties, there is currently no in silico analog for antibody design. Here, we model the variable domain structures of a large set of post-Phase I clinical-stage antibody therapeutics (CSTs), and calculate an array of metrics to estimate their typical properties. In each case, we contextualize the CST distribution against a snapshot of the human antibody gene repertoire. We describe guideline values for five metrics thought to be implicated in poor developability: the total length of the Complementarity-Determining Regions (CDRs), the extent and magnitude of surface hydrophobicity, positive charge and negative charge in the CDRs, and asymmetry in the net heavy and light chain surface charges. The guideline cut-offs for each property were derived from the values seen in CSTs, and a flagging system is proposed to identify nonconforming candidates. On two mAb drug discovery sets, we were able to selectively highlight sequences with developability issues. We make available the Therapeutic Antibody Profiler (TAP), an open-source computational tool that builds downloadable homology models of variable domain sequences, tests them against our five developability guidelines, and reports potential sequence liabilities and canonical forms. TAP is freely available at http://opig.stats.ox.ac.uk/webapps/sabdab-sabpred/TAP.php.

immunology↗